Skip to main content

This platform is for Australian healthcare professionals only

Home | go to homepage
SCIENCE
  • SCIENCE
  • Anticoagulation
  • Cardiovascular
    • Cardiovascular
    • Lipid Management
      • Lipid Management
      • Video Library
        • Video Library
        • Intensive secondary prevention of ASCVD: The who, why and how
        • Reducing residual ASCVD risk: Who are your highest risk patients that can benefit the most?
        • Reducing residual ASCVD risk: The urgency beyond the ACS emergency
        • LDL-C: How low can we go in our highest risk patients?
        • Dr Warrick Bishop - Praluent® (alirocumab) PBS Assist tool
        • Prof Shaun Goodman summarises the ODYSSEY OUTCOMES clinical trial
        • Who will benefit most from PCSK9 inhibitor
        • Working with other healthcare providers to help patients achieve their LDL-C goals
        • Prof Shaun Goodman: How do you empower your patients post-ACS?
        • How do you show post-ACS patients the importance of achieving their LDL-C goals?
        • Professor Shaun Goodman's one piece of advice for a patient post-ACS
        • ASCVD: What's the difference in the management of primary and secondary prevention?
        • Which patients are missed by the system after an ACS?
        • Prof. Shaun Goodman: What do patients need to know most about managing their cholesterol post-ACS?
        • Current Trends in Dyslipidaemia Management
        • Intensification of Lipid Lowering Therapy: Treating to Guideline Recommended LDL-C Targets in Clinical Practice
  • Diabetes
    • Diabetes
    • Importance of glycaemic control
    • Achieving glycaemic control with insulin
    • Video Library
      • Video Library
      • RACGP Guidelines Module 1: Refreshing Key Concepts of Type 2 Diabetes
      • RACGP Guidelines Module 2: Type 2 Diabetes - Special Populations
      • RACGP Guidelines Module 3: An Update on Microvascular Complications
      • RACGP Guidelines Module 4: An Update on Diabetes and Cardiovascular Disease
      • RACGP Guidelines Module 5: Mastering The Management of Type 2 Diabetes – Part 1
      • RACGP Guidelines Module 6: Mastering The Management of Type 2 Diabetes – Part 2
      • Prof Rory McCrimmon on Why Hypoglycaemia Should be Top of Mind
      • Prof Rory McCrimmon on the Impact of Hypoglycaemia
      • Prof Rory McCrimmon: Patients at Risk of Hypoglycaemia
      • Prof Rory McCrimmon: Why is Nocturnal Hypoglycaemia Important?
      • Prof Rory McCrimmon: What is Impaired Hypogylcaemia Awareness?
      • Prof Rory McCrimmon: The Impact of Impaired Hypogylcaemia Awareness
      • Prof Rory McCrimmon: Preventing Hypoglycaemia
      • Prof Rory McCrimmon: Preventing Hypos: Insulin Optimisation
      • Diabetes and Exercise, Dr Angela Lee
      • Diabetes and Ramadan Webinar with endocrinologist, Dr Marwan Obaid
      • Individualising Diabetes Care and Evolution of Glucose Management, Dr Sybil McAuley
      • Practical Applications of Constant Glucose Monitoring in diabetes, Dr Emma Scott
      • The Stigma of Diabetes, Prof. Jane Speight
      • Trends in T2DM and Future Research Directions, Prof. Jonathan Shaw
      • How to inject Toujeo (insulin glargine 300U/mL)
      • How to Inject Optisulin (insulin glargine 100U/mL)
  • Pharmacy
    • Pharmacy
    • Pharmacy Resource Request Form
  • Rare Blood Disorders
    • Rare Blood Disorders
    • Haemophilia
      • Haemophilia
      • A-LONG Phase 3 study of rFVIIIFc in haemophilia A adults and adolescents
      • Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A
      • A Matched Adjusted Indirect Comparison analysis of emicizumab and rFVIIIFc efficacy
      • Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study
      • Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein
      • Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B
      • Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG)
      • Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B-YOND extension study
      • Contact your local Haemophilia Account Executive
    • Video Library
      • Video Library
      • Make a change today
      • Interim analysis of B-SURE study on real world usage and effectiveness of rFIXFc
      • Real world effectiveness and usage of rFIXFc in surgery from B-SURE study
      • Joint health in the bleeding disorders community
      • Bring Your A Game Webinar Featuring Dr Guy Young
      • Bring Your A Game webinar - Klamroth excerpt
      • The priority is protection - The right regimen to achieve desired outcomes
  • Rare Disease
    • Rare Disease
    • Fabry Disease
      • Fabry Disease
      • About Fabry
      • Fabry signs and symptoms
      • Clinical Presentation
      • How to make a diagnosis
      • Testing and screening
      • Treatment options
      • Guide to reducing the infusion time with Fabrazyme
      • Hereditary Diseases Podcasts
      • Fabrazyme reconstitution and administration video
      • Clinical Papers
      • Professor Perry Elliot 8 essential elements in the diagnosis of hypertrophic cardiomyopathy
      • Professor Namdar on the value of ECG assessment for early recognition and diagnosis of inherited cardiomyopathies
      • Video Library
        • Video Library
        • Prof Namdar - Diagnosis of Hypertrophic Cardiomyopathies Based on ECG Parameters
        • Dr Kozor - What is the Significance of LGE in Fabry Disease?
        • Dr Kozor - How Can Papillary Muscles Differentiate Hypertrophic Hearts in Fabry Disease?
        • Dr Kozor - Role of Cardiac MRI in Fabry Disease
        • Dr Kozor - What Can CMR Tell Us About Patients with Fabry Disease?
        • Dr Tchan & Prof Thomas - Fabry Disease - The Hypertrophic Cardiomyopathy Imposter
        • Prof Namdar - Differentiation Between Infiltrative Cardiomyopathies Based on ECG Parameters
        • Prof Namdar - Management of Conduction Abnormalities and Arrhythmia in Fabry Cardiomyopathy
        • Prof Namdar - Differentiation Between Hypertrophic Cardiomyopathy & Athlete's Heart (ECG parameters)
        • Prof Namdar - Electrocardiographic Abnormalities & Arrhythmia in Cardiomyopathies
        • Dr Kozor - What Can T1 Mapping Tell Us About Cardiac Structure and Function in Fabry Disease?
        • A/Prof Jodie Ingles - Genetic Testing and Counselling for Inherited Cardiovascular Diseases
        • Dr Alison McLean - Clinician Guide to Ordering a Genetic Test
        • Dr Leslie Burnett - Interpreting a Genomics Report
        • Laura Yeates - Preparing your patient for genetic testing
        • Prof Chris Semsarian AM - Clinical Utility of Genetic Testing in Cardiac Disorders
        • Dr Pieroni - Watch Out for the Red Flags for Fabry Disease to Avoid Missing the Diagnosis
        • Prof John A Sayer - Family, Phenotype, Fabry (Case Study 1)
        • Prof John A Sayer - Beware of Autopilot CKD (Case Study 2)
        • Prof John A Sayer - Beware of pre-existing diagnostics labels (Case Study 3)
        • Prof John A Sayer - Atypical presentation of Fabry Females (Case Study 4)
        • Fabrazyme reconstitution and administration video
        • Dr Pieroni - Challenges in Cardiology during the COVID-19 Pandemic
        • Assoc Prof Thomas - High Risk Population Screening and Multidisciplinary Clinic
        • Dr Rick Steeds - Introduction to Fabry Disease
        • Dr Rick Steeds - Fabry & Families (Case Study 1)
        • Dr Rick Steeds - Fabry & the Passage of Time (Case Study 2)
        • Dr Ashwin Roy - Fabry, The Heart & Beyond (Case Study 3)
        • Dr Ashwin Roy - Fabry & Lifestyle (Case Study 4)
    • Pompe Disease
      • Pompe Disease
      • What is Pompe disease
      • Pompe disease overview
      • Clinical presentation and progression
      • Diagnosis and testing
      • Disease management
      • Multidisciplinary care
      • Clinical Papers - Pompe Disease
      • Pompe Diseases Podcasts
      • Video Library
        • Video Library
        • Raised CO₂ and Neuromuscular Disorders - Prof. Pitt Young Q&A Series
        • Why is Respiratory Knowledge Essential to Neurology? - Prof. Pitt Young Q&A Series
        • Neurologic Assessment of Breathing Dysfunction - Prof. Pitt Young Q&A Series
        • Ageing and Sleep Disturbance Prof. Pitt Young Q&A Series
        • Timing of Monitoring Respiratory Function in NMD - Prof. Pitt Young Q&A Series
        • Is Diagnosis of Late-Onset Pompe Disease Being Delayed or Missed? - Prof. Pitt Young Q&A Series
        • Which Neuromuscular Diseases Have an Impact on Breathing? - Prof. Pitt Young Q&A Series
        • Clinical Signs of Pompe Disease - Prof. Pitt Young Q&A Series
        • Diagnostic Approach to Diaphragmatic Weakness - Prof. Pitt Young Q&A Series
        • Importance of an Early Diagnosis of Late-Onset Pompe Disease - Prof. Pitt Young Q&A Series
        • Red Flags for Late-Onset Pompe Disease - Prof. Pitt Young Q&A Series
        • Signs of Limb Girdle Weakness - Prof. Pitt Young Q&A Series
        • New Diagnostic Approaches in Neuromuscular Disorders - Prof. Benedikt Schoser Short Video
        • Red Flags for diagnosis of Pompe Disease - Prof. Merrilee Needham
        • Neuromuscular Disorders with Respiratory Involvement - Prof. Pitt Young Presentation
        • Case Studies of Pompe Disease - Prof. Benedikt Schoser
        • Case Study of Pompe Disease in a 36 Year Old Female - Prof. Pitt Young
        • Role of General Neurologists in Diagnosing Pompe Disease - Prof. Benedikt Schoser Short Video
        • Case Study of Pompe Disease in a 64 Year Old Male - Prof. Pitt Young
        • Pompe Disease Overview and Diagnostic Journey
        • Preparation of Myozyme Infusion: Video Demonstration
        • Myozyme (alglucosidase alfa) Mechanism of Action
    • Gaucher Disease
      • Gaucher Disease
      • About Gaucher Disease
      • Gaucher Disease signs and symptoms
      • Gaucher disease clinical presentation
      • Gaucher Disease Diagnosis
      • Gaucher disease testing and screening
      • Gaucher disease treatment options
      • Gaucher Disease Management of the condition
    • MPS I & II
      • MPS I & II
      • About MPS I & II
      • MPS I & II Signs and Symptoms
      • MPS I & II Clinical Presentation
      • MPS I & II Disease Spectrum
      • MPS I & II Diagnosis
      • MPS I & II Testing and Screening
      • MPS I & II Treatment
      • MPS I & II Management of the Condition
    • Diagnostic Testing
  • Respiratory
    • Respiratory
    • Asthma
      • Asthma
      • Type 2 inflammation
      • IL-4-and-IL-13
      • Clinical Trials
      • Peter Wark's Podcast with Inside Practice
      • TRAVERSE publication
      • VENTURE publication
      • QUEST publication
      • Type 2 Inflammation in severe asthma
      • Advent Asthma
    • CRSwNP (Chronic Rhinosinusitis with Nasal Polyps)
      • CRSwNP (Chronic Rhinosinusitis with Nasal Polyps)
      • Type 2 inflammation
      • IL-4-and-IL-13
      • Advent CRSwNP
      • Clinical Trials
      • SINUS-24 and SINUS-52 publication
PATIENT SUPPORT
  • PATIENT SUPPORT
  • Anticoagulation
    • Anticoagulation
    • Clexane (enoxaparin sodium) Dosing Guide
    • Clexane (enoxaparin sodium) Safety Lock Instructions in Arabic
    • Clexane (enoxaparin sodium) Safety Lock Instructions in English
    • Mandarin Clexane (enoxaparin sodium) Safety Lock Instructions
    • Greek Clexane (enoxaparin sodium) Safety Lock Instructions
    • Italian Clexane (enoxaparin sodium) Safety Lock Instructions
    • Vietnamese Clexane (enoxaparin sodium) Safety Lock Instructions
    • Patient Guide: Preventing and Treating Blood Clots
    • Clexane Safety Lock Training Presentations for Healthcare Professionals
    • How to Inject Clexane (enoxaparin sodium) Video for Patients
    • Clexane (enoxaparin sodium) Safety Lock Instructional Video for Healthcare Professionals
    • VTE Matters: A Patient Support Website
  • Cardiovascular
    • Cardiovascular
    • My Praluent Coach
    • My Praluent Coach Patient Guide
    • Praluent (alirocumab) Patient Injection Guide Video
    • PBS Assist
  • Diabetes
    • Diabetes
    • Optisulin, Toujeo & Apidra Starter Pack Request Form
    • A guide to managing patients with T2DM who fast during Ramadan
    • Request Sanofi Diabetes resources
    • Access Simple Steps: Support for insulin Patients
    • A Guide to Starting Optisulin (insulin glargine 100 units/mL) for People Living with Type 1 Diabetes
    • A Guide to Starting Optisulin (insulin glargine 100 units/mL) for People Living with Type 2 Diabetes
    • Optisulin (insulin glargine 100 units/mL) SoloStar Instructions For Use
  • Pharmacy
    • Pharmacy
    • Pharmacy Resources
  • Rare Disease
    • Rare Disease
    • Pompe Disease
      • Pompe Disease
      • Care4Rare Patient Program
      • Patient Support Groups
      • Patient alert card
      • Patient Documents
    • Gaucher
      • Gaucher
      • Gaucher Patient Support Groups
      • Gaucher Home Infusion Program
    • MPS I & II
      • MPS I & II
      • MPS I & II Patient Support Groups
      • MPS II Home Infusion Program
    • Fabry
      • Fabry
      • Care4Rare Patient Program
      • Patient Support Groups
      • Fabry Pain Diary App
      • Home Infusion Program
  • Rare Blood Disorders
    • Rare Blood Disorders
    • Haemophilia
      • Haemophilia
      • Getting started with ELOCTATE
      • Getting started with ALPROLIX
      • ELOCTATE Reconstitution Guide
      • ALPROLIX Reconstitution Guide
      • Patient Starter Kit
      • Active health booklet
      • Patient Enrolment Form
      • Product Order Form
      • Alprolix Cycle Order Form
      • Eloctate Cycle Order Form
      • Why Choose ALPROLIX
      • ALPROLIX On-Demand to Prophylaxis
      • Prophylaxis treatment of haemophilia B with ALPROLIX
      • Why Choose ELOCTATE
      • Prophylaxis treatment of haemophilia A with ELOCTATE
      • Factor in the Future with ELOCTATE
      • On-demand treamtment of haemophilia A with ELOCTATE
      • Contact your local Haemophilia Account Executive
    • Video Library
      • Video Library
      • Working out a new approach
      • Are you diagnosed
      • Why advocating for your own
      • Aug R joint scanner
      • Wills End comic
  • Respiratory
    • Respiratory
    • Asthma
      • Asthma
      • Video Library
        • Video Library
        • Dupixent (dupilumab) self-injection training video
        • Dupixent (dupilumab) caregiver's injection training video
      • Dupixent (dupilumab) Guide to treatment
      • MyWaySupport Program Enrolment Form: for patient self-enrolment
      • Dupixent (dupilumab) MyWaySupport Program Overview
      • Dupixent (dupilumab) injection guide
    • CRSwNP
      • CRSwNP
      • Dupixent (dupilumab) self-injection training video
      • Dupixent (dupilumab) caregiver's injection training video
      • Dupixent (dupilumab) Guide to treatment
      • Dupixent (dupilumab) injection guide
PRODUCTS
Search
Login
Register
Home | go to homepage
Search
Login
Register
Home | go to homepage
SCIENCE
  • SCIENCE
  • Anticoagulation
  • Cardiovascular
    • Cardiovascular
    • Lipid Management
      • Lipid Management
      • Video Library
        • Video Library
        • Intensive secondary prevention of ASCVD: The who, why and how
        • Reducing residual ASCVD risk: Who are your highest risk patients that can benefit the most?
        • Reducing residual ASCVD risk: The urgency beyond the ACS emergency
        • LDL-C: How low can we go in our highest risk patients?
        • Dr Warrick Bishop - Praluent® (alirocumab) PBS Assist tool
        • Prof Shaun Goodman summarises the ODYSSEY OUTCOMES clinical trial
        • Who will benefit most from PCSK9 inhibitor
        • Working with other healthcare providers to help patients achieve their LDL-C goals
        • Prof Shaun Goodman: How do you empower your patients post-ACS?
        • How do you show post-ACS patients the importance of achieving their LDL-C goals?
        • Professor Shaun Goodman's one piece of advice for a patient post-ACS
        • ASCVD: What's the difference in the management of primary and secondary prevention?
        • Which patients are missed by the system after an ACS?
        • Prof. Shaun Goodman: What do patients need to know most about managing their cholesterol post-ACS?
        • Current Trends in Dyslipidaemia Management
        • Intensification of Lipid Lowering Therapy: Treating to Guideline Recommended LDL-C Targets in Clinical Practice
  • Diabetes
    • Diabetes
    • Importance of glycaemic control
    • Achieving glycaemic control with insulin
    • Video Library
      • Video Library
      • RACGP Guidelines Module 1: Refreshing Key Concepts of Type 2 Diabetes
      • RACGP Guidelines Module 2: Type 2 Diabetes - Special Populations
      • RACGP Guidelines Module 3: An Update on Microvascular Complications
      • RACGP Guidelines Module 4: An Update on Diabetes and Cardiovascular Disease
      • RACGP Guidelines Module 5: Mastering The Management of Type 2 Diabetes – Part 1
      • RACGP Guidelines Module 6: Mastering The Management of Type 2 Diabetes – Part 2
      • Prof Rory McCrimmon on Why Hypoglycaemia Should be Top of Mind
      • Prof Rory McCrimmon on the Impact of Hypoglycaemia
      • Prof Rory McCrimmon: Patients at Risk of Hypoglycaemia
      • Prof Rory McCrimmon: Why is Nocturnal Hypoglycaemia Important?
      • Prof Rory McCrimmon: What is Impaired Hypogylcaemia Awareness?
      • Prof Rory McCrimmon: The Impact of Impaired Hypogylcaemia Awareness
      • Prof Rory McCrimmon: Preventing Hypoglycaemia
      • Prof Rory McCrimmon: Preventing Hypos: Insulin Optimisation
      • Diabetes and Exercise, Dr Angela Lee
      • Diabetes and Ramadan Webinar with endocrinologist, Dr Marwan Obaid
      • Individualising Diabetes Care and Evolution of Glucose Management, Dr Sybil McAuley
      • Practical Applications of Constant Glucose Monitoring in diabetes, Dr Emma Scott
      • The Stigma of Diabetes, Prof. Jane Speight
      • Trends in T2DM and Future Research Directions, Prof. Jonathan Shaw
      • How to inject Toujeo (insulin glargine 300U/mL)
      • How to Inject Optisulin (insulin glargine 100U/mL)
  • Pharmacy
    • Pharmacy
    • Pharmacy Resource Request Form
  • Rare Blood Disorders
    • Rare Blood Disorders
    • Haemophilia
      • Haemophilia
      • A-LONG Phase 3 study of rFVIIIFc in haemophilia A adults and adolescents
      • Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A
      • A Matched Adjusted Indirect Comparison analysis of emicizumab and rFVIIIFc efficacy
      • Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study
      • Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein
      • Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B
      • Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG)
      • Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B-YOND extension study
      • Contact your local Haemophilia Account Executive
    • Video Library
      • Video Library
      • Make a change today
      • Interim analysis of B-SURE study on real world usage and effectiveness of rFIXFc
      • Real world effectiveness and usage of rFIXFc in surgery from B-SURE study
      • Joint health in the bleeding disorders community
      • Bring Your A Game Webinar Featuring Dr Guy Young
      • Bring Your A Game webinar - Klamroth excerpt
      • The priority is protection - The right regimen to achieve desired outcomes
  • Rare Disease
    • Rare Disease
    • Fabry Disease
      • Fabry Disease
      • About Fabry
      • Fabry signs and symptoms
      • Clinical Presentation
      • How to make a diagnosis
      • Testing and screening
      • Treatment options
      • Guide to reducing the infusion time with Fabrazyme
      • Hereditary Diseases Podcasts
      • Fabrazyme reconstitution and administration video
      • Clinical Papers
      • Professor Perry Elliot 8 essential elements in the diagnosis of hypertrophic cardiomyopathy
      • Professor Namdar on the value of ECG assessment for early recognition and diagnosis of inherited cardiomyopathies
      • Video Library
        • Video Library
        • Prof Namdar - Diagnosis of Hypertrophic Cardiomyopathies Based on ECG Parameters
        • Dr Kozor - What is the Significance of LGE in Fabry Disease?
        • Dr Kozor - How Can Papillary Muscles Differentiate Hypertrophic Hearts in Fabry Disease?
        • Dr Kozor - Role of Cardiac MRI in Fabry Disease
        • Dr Kozor - What Can CMR Tell Us About Patients with Fabry Disease?
        • Dr Tchan & Prof Thomas - Fabry Disease - The Hypertrophic Cardiomyopathy Imposter
        • Prof Namdar - Differentiation Between Infiltrative Cardiomyopathies Based on ECG Parameters
        • Prof Namdar - Management of Conduction Abnormalities and Arrhythmia in Fabry Cardiomyopathy
        • Prof Namdar - Differentiation Between Hypertrophic Cardiomyopathy & Athlete's Heart (ECG parameters)
        • Prof Namdar - Electrocardiographic Abnormalities & Arrhythmia in Cardiomyopathies
        • Dr Kozor - What Can T1 Mapping Tell Us About Cardiac Structure and Function in Fabry Disease?
        • A/Prof Jodie Ingles - Genetic Testing and Counselling for Inherited Cardiovascular Diseases
        • Dr Alison McLean - Clinician Guide to Ordering a Genetic Test
        • Dr Leslie Burnett - Interpreting a Genomics Report
        • Laura Yeates - Preparing your patient for genetic testing
        • Prof Chris Semsarian AM - Clinical Utility of Genetic Testing in Cardiac Disorders
        • Dr Pieroni - Watch Out for the Red Flags for Fabry Disease to Avoid Missing the Diagnosis
        • Prof John A Sayer - Family, Phenotype, Fabry (Case Study 1)
        • Prof John A Sayer - Beware of Autopilot CKD (Case Study 2)
        • Prof John A Sayer - Beware of pre-existing diagnostics labels (Case Study 3)
        • Prof John A Sayer - Atypical presentation of Fabry Females (Case Study 4)
        • Fabrazyme reconstitution and administration video
        • Dr Pieroni - Challenges in Cardiology during the COVID-19 Pandemic
        • Assoc Prof Thomas - High Risk Population Screening and Multidisciplinary Clinic
        • Dr Rick Steeds - Introduction to Fabry Disease
        • Dr Rick Steeds - Fabry & Families (Case Study 1)
        • Dr Rick Steeds - Fabry & the Passage of Time (Case Study 2)
        • Dr Ashwin Roy - Fabry, The Heart & Beyond (Case Study 3)
        • Dr Ashwin Roy - Fabry & Lifestyle (Case Study 4)
    • Pompe Disease
      • Pompe Disease
      • What is Pompe disease
      • Pompe disease overview
      • Clinical presentation and progression
      • Diagnosis and testing
      • Disease management
      • Multidisciplinary care
      • Clinical Papers - Pompe Disease
      • Pompe Diseases Podcasts
      • Video Library
        • Video Library
        • Raised CO₂ and Neuromuscular Disorders - Prof. Pitt Young Q&A Series
        • Why is Respiratory Knowledge Essential to Neurology? - Prof. Pitt Young Q&A Series
        • Neurologic Assessment of Breathing Dysfunction - Prof. Pitt Young Q&A Series
        • Ageing and Sleep Disturbance Prof. Pitt Young Q&A Series
        • Timing of Monitoring Respiratory Function in NMD - Prof. Pitt Young Q&A Series
        • Is Diagnosis of Late-Onset Pompe Disease Being Delayed or Missed? - Prof. Pitt Young Q&A Series
        • Which Neuromuscular Diseases Have an Impact on Breathing? - Prof. Pitt Young Q&A Series
        • Clinical Signs of Pompe Disease - Prof. Pitt Young Q&A Series
        • Diagnostic Approach to Diaphragmatic Weakness - Prof. Pitt Young Q&A Series
        • Importance of an Early Diagnosis of Late-Onset Pompe Disease - Prof. Pitt Young Q&A Series
        • Red Flags for Late-Onset Pompe Disease - Prof. Pitt Young Q&A Series
        • Signs of Limb Girdle Weakness - Prof. Pitt Young Q&A Series
        • New Diagnostic Approaches in Neuromuscular Disorders - Prof. Benedikt Schoser Short Video
        • Red Flags for diagnosis of Pompe Disease - Prof. Merrilee Needham
        • Neuromuscular Disorders with Respiratory Involvement - Prof. Pitt Young Presentation
        • Case Studies of Pompe Disease - Prof. Benedikt Schoser
        • Case Study of Pompe Disease in a 36 Year Old Female - Prof. Pitt Young
        • Role of General Neurologists in Diagnosing Pompe Disease - Prof. Benedikt Schoser Short Video
        • Case Study of Pompe Disease in a 64 Year Old Male - Prof. Pitt Young
        • Pompe Disease Overview and Diagnostic Journey
        • Preparation of Myozyme Infusion: Video Demonstration
        • Myozyme (alglucosidase alfa) Mechanism of Action
    • Gaucher Disease
      • Gaucher Disease
      • About Gaucher Disease
      • Gaucher Disease signs and symptoms
      • Gaucher disease clinical presentation
      • Gaucher Disease Diagnosis
      • Gaucher disease testing and screening
      • Gaucher disease treatment options
      • Gaucher Disease Management of the condition
    • MPS I & II
      • MPS I & II
      • About MPS I & II
      • MPS I & II Signs and Symptoms
      • MPS I & II Clinical Presentation
      • MPS I & II Disease Spectrum
      • MPS I & II Diagnosis
      • MPS I & II Testing and Screening
      • MPS I & II Treatment
      • MPS I & II Management of the Condition
    • Diagnostic Testing
  • Respiratory
    • Respiratory
    • Asthma
      • Asthma
      • Type 2 inflammation
      • IL-4-and-IL-13
      • Clinical Trials
      • Peter Wark's Podcast with Inside Practice
      • TRAVERSE publication
      • VENTURE publication
      • QUEST publication
      • Type 2 Inflammation in severe asthma
      • Advent Asthma
    • CRSwNP (Chronic Rhinosinusitis with Nasal Polyps)
      • CRSwNP (Chronic Rhinosinusitis with Nasal Polyps)
      • Type 2 inflammation
      • IL-4-and-IL-13
      • Advent CRSwNP
      • Clinical Trials
      • SINUS-24 and SINUS-52 publication
PATIENT SUPPORT
  • PATIENT SUPPORT
  • Anticoagulation
    • Anticoagulation
    • Clexane (enoxaparin sodium) Dosing Guide
    • Clexane (enoxaparin sodium) Safety Lock Instructions in Arabic
    • Clexane (enoxaparin sodium) Safety Lock Instructions in English
    • Mandarin Clexane (enoxaparin sodium) Safety Lock Instructions
    • Greek Clexane (enoxaparin sodium) Safety Lock Instructions
    • Italian Clexane (enoxaparin sodium) Safety Lock Instructions
    • Vietnamese Clexane (enoxaparin sodium) Safety Lock Instructions
    • Patient Guide: Preventing and Treating Blood Clots
    • Clexane Safety Lock Training Presentations for Healthcare Professionals
    • How to Inject Clexane (enoxaparin sodium) Video for Patients
    • Clexane (enoxaparin sodium) Safety Lock Instructional Video for Healthcare Professionals
    • VTE Matters: A Patient Support Website
  • Cardiovascular
    • Cardiovascular
    • My Praluent Coach
    • My Praluent Coach Patient Guide
    • Praluent (alirocumab) Patient Injection Guide Video
    • PBS Assist
  • Diabetes
    • Diabetes
    • Optisulin, Toujeo & Apidra Starter Pack Request Form
    • A guide to managing patients with T2DM who fast during Ramadan
    • Request Sanofi Diabetes resources
    • Access Simple Steps: Support for insulin Patients
    • A Guide to Starting Optisulin (insulin glargine 100 units/mL) for People Living with Type 1 Diabetes
    • A Guide to Starting Optisulin (insulin glargine 100 units/mL) for People Living with Type 2 Diabetes
    • Optisulin (insulin glargine 100 units/mL) SoloStar Instructions For Use
  • Pharmacy
    • Pharmacy
    • Pharmacy Resources
  • Rare Disease
    • Rare Disease
    • Pompe Disease
      • Pompe Disease
      • Care4Rare Patient Program
      • Patient Support Groups
      • Patient alert card
      • Patient Documents
    • Gaucher
      • Gaucher
      • Gaucher Patient Support Groups
      • Gaucher Home Infusion Program
    • MPS I & II
      • MPS I & II
      • MPS I & II Patient Support Groups
      • MPS II Home Infusion Program
    • Fabry
      • Fabry
      • Care4Rare Patient Program
      • Patient Support Groups
      • Fabry Pain Diary App
      • Home Infusion Program
  • Rare Blood Disorders
    • Rare Blood Disorders
    • Haemophilia
      • Haemophilia
      • Getting started with ELOCTATE
      • Getting started with ALPROLIX
      • ELOCTATE Reconstitution Guide
      • ALPROLIX Reconstitution Guide
      • Patient Starter Kit
      • Active health booklet
      • Patient Enrolment Form
      • Product Order Form
      • Alprolix Cycle Order Form
      • Eloctate Cycle Order Form
      • Why Choose ALPROLIX
      • ALPROLIX On-Demand to Prophylaxis
      • Prophylaxis treatment of haemophilia B with ALPROLIX
      • Why Choose ELOCTATE
      • Prophylaxis treatment of haemophilia A with ELOCTATE
      • Factor in the Future with ELOCTATE
      • On-demand treamtment of haemophilia A with ELOCTATE
      • Contact your local Haemophilia Account Executive
    • Video Library
      • Video Library
      • Working out a new approach
      • Are you diagnosed
      • Why advocating for your own
      • Aug R joint scanner
      • Wills End comic
  • Respiratory
    • Respiratory
    • Asthma
      • Asthma
      • Video Library
        • Video Library
        • Dupixent (dupilumab) self-injection training video
        • Dupixent (dupilumab) caregiver's injection training video
      • Dupixent (dupilumab) Guide to treatment
      • MyWaySupport Program Enrolment Form: for patient self-enrolment
      • Dupixent (dupilumab) MyWaySupport Program Overview
      • Dupixent (dupilumab) injection guide
    • CRSwNP
      • CRSwNP
      • Dupixent (dupilumab) self-injection training video
      • Dupixent (dupilumab) caregiver's injection training video
      • Dupixent (dupilumab) Guide to treatment
      • Dupixent (dupilumab) injection guide
PRODUCTS
  • Search
  • Login
  • Register
    • Home
    • Science
    • Cardiovascular
    • Lipid Management
    • Video Library

    Video Library

    00:17:24.00

    Reducing residual ASCVD risk: Who are your highest risk patients that can benefit the most?
    00:08:37.00

    Dr Warrick Bishop - Praluent® (alirocumab) PBS Assist tool
    00:03:30.00

    Intensive secondary prevention of ASCVD: The who, why and how
    00:04:37.00

    Current Trends in Dyslipidaemia Management
    00:15:27.00

    Reducing residual ASCVD risk: The urgency beyond the ACS emergency
    00:02:39.00

    Who will benefit most from PCSK9 inhibitor
    00:16:32.00

    LDL-C: How low can we go in our highest risk patients?
    00:02:20.00

    Prof Shaun Goodman summarises the ODYSSEY OUTCOMES clinical trial
    00:03:06.00

    Which patients are missed by the system after an ACS?
    00:01:34.00

    Prof Shaun Goodman: How do you empower your patients post-ACS?
    00:02:24

    Working with other healthcare providers to help patients achieve their LDL-C goals
    00:01:26.00

    Professor Shaun Goodman's one piece of advice for a patient post-ACS
    00:03:09.00

    ASCVD: What's the difference in the management of primary and secondary prevention?
    00:01:46

    How do you show post-ACS patients the importance of achieving their LDL-C goals?
    00:03:36.00

    Intensification of Lipid Lowering Therapy: Treating to Guideline Recommended LDL-C Targets in Clinical Practice
    00:01:33.00

    Prof. Shaun Goodman: What do patients need to know most about managing their cholesterol post-ACS?
    Home | go to homepage

    sanofi-aventis australia pty ltd
    trading as Sanofi. ABN 31 008 558 807
    Talavera Corporate Centre
    Building D, 12-24 Talavera Road
    Macquarie Park, NSW 2113

    • About
    • Contact us
    • Cookie policy
    • Legal notice
    • Privacy notice
    • Site map

    © Sanofi 2022 – All rights reserved.

    YOU WILL NOW BE LEAVING THE SITE

    You are now leaving campus.sanofi/au

    Campus Sanofi Australia does not review the information contained on this website and/or database for content, accuracy or completeness. Use of and access to this information is subject to the terms, limitations and conditions set by the website and/or database producer.

    Campus Sanofi Australia makes no representation as to the accuracy or any other aspect of the information contained on such website and/or database, nor does Campus Sanofi Australia necessarily endorse such website and/or database.
    The information the reader is about to be referred to may not comply with the Australian regulatory requirements. Further information relevant to the Australian environment is available from the company or via the Product Information.

    Continue

    This website is intended exclusively for healthcare professionals residing and/or working in Australia.

     

    Please choose if you are a healthcare professional and wish to continue on this site or if you are a member of the public to be redirected to the Sanofi website.